{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-26-001071","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2026-08-11T11:05:36+00:00","discovered_at":"2026-08-11T11:10:00.404220+00:00","generated_at":"2026-08-11T11:10:25.254460+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Immunic Q2 2026 net loss $34.1M; ENSURE top-line data expected by year-end; Ridloff joins board","bullets":["Q2 2026 net loss $34.1M ($0.80/share) vs $26.8M ($2.03/share) in Q2 2025; R&D spend $25.9M.","Cash and equivalents $155.1M at June 30, 2026; expected to fund operations into late 2027.","Phase 3 ENSURE relapsing MS top-line data expected by end of 2026; NDA submission mid-2027 if positive.","Elena Ridloff appointed to Board Aug 6, 2026; received options for 50,740 shares.","Daniel Vitt resigned from Board; separation agreement provides $670K lump sum, $276K bonus, 100% equity vesting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-26-001071","json":"https://secwatch.observer/filing/0001193805-26-001071.json","markdown":"https://secwatch.observer/filing/0001193805-26-001071.md","text":"https://secwatch.observer/filing/0001193805-26-001071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526001071/0001193805-26-001071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526001071/e665684_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T11:10:25.254460+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}